NASDAQ$AURA
Aura Biosciences Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results and provided clinical development and operational highlights.
Aura Biosciences reported second quarter financial results, highlighting the progress in advancing belzupacap sarotalocan's clinical development, including plans to dose the first patient in the Phase 1 trial for NMIBC in Q3 2022 and initiate a pivotal trial in early-stage choroidal melanoma in Q4 2022.
- On track to dose the first patient in the Phase 1 study evaluating Belzupacap Sarotalocan (AU-011) for the treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022.
- On track to initiate pivotal trial in early-stage choroidal melanoma in Q4 2022.
- FDA granted Fast Track designation for belzupacap sarotalocan for the treatment of NMIBC.
- Aura plans to file an IND for choroidal metastases in Q4 of 2022.
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$600K
Forward guidance
Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q2 2022
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro